Bottom Line: People on GLP-1s Should Be Monitored for Health Changes Experts say the findings should not discourage appropriate use of GLP-1 medications, which provide significant benefits for many people with diabetes and obesity, including improvements in heart health, kidney function, and liver disease
Studies show that liposomal delivery enhances glutathiones bioavailability, leading to more direct and sustained health benefits such as improved antioxidant protection and immune support
Mechanisms Mediating Renal Secretion of Organic Anions and Cations
The IGF1 LR3 is the agonist of IGF1 and has improved metabolic stability
Baseline labs: IGF-1, fasting glucose, HbA1c, lipid panel, and comprehensive metabolic panel are standard before initiation